ADVISORY/FDA Approves Novartis Agent ZOMETA For Treatment of Hypercalcemia of Malignancy.Business Editors & Health/Medical Writers ADVISORY...for TUESDAY (Aug. 21) NOTE TO EDITORS: Multimedia Assets Available With This Story Include Logos, Text News Releases, Video --(BUSINESS WIRE) Novartis announced it has received marketing approval from the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for ZOMETA(R) (zoledronic acid zoledronic acid /zo·le·dron·ic ac·id/ (zo´le-dron?ik) a bisphosphonate inhibitor of osteoclastic bone resorption, used for the treatment of hypercalcemia of malignancy. for injection; zo MET uh), a new generation intravenous (IV) bisphosphonate for the treatment of hypercalcemia of malignancy hypercalcemia of malignancy A clinical complex, 50% of which results from hypersecretion of parathyroid hormone-related protein–PTHRP, aka parathyroid hormone-related peptide; HCM may result from either direct replacement–eg, in lympho- and (HCM HCM hypertrophic cardiomyopathy. ). HCM is the most common life-threatening metabolic complication complication /com·pli·ca·tion/ (kom?pli-ka´shun) 1. disease(s) concurrent with another disease. 2. occurrence of several diseases in the same patient. com·pli·ca·tion n. associated with cancer. Video news release available here. You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?3756 This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos. If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion